Monte Rosa Therapeutics, Inc. (GLUE) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: 13.50
30Y Low13.5·High13.5
P/B Ratio
↑
6.10
↑+125% vs avg
5yr avg: 2.71
30Y Low1.3·High5.6
ROE
↑
-16.9%
↓+57% vs avg
5yr avg: -39.5%
30Y Low-60%·High-17%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
GLUE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Monte Rosa Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $1.3B | $513M | $290M | $359M | $950M | — | — |
| Enterprise Value | $1.0B | $1.2B | $331M | $208M | $351M | $604M | — | — |
| P/E Ratio → | -37.17 | — | — | — | — | — | — | — |
| P/S Ratio | 9.00 | 10.53 | 6.78 | — | — | — | — | — |
| P/B Ratio | 6.10 | 5.59 | 2.30 | 1.62 | 1.32 | 2.73 | — | — |
| P/FCF | — | — | 13.50 | — | — | — | — | — |
| P/OCF | — | — | 12.21 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
GLUE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 9.80 | 4.38 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | 8.72 | — | — | — | — | — |
GLUE Profitability
Margins and return-on-capital ratios measuring operating efficiency
Monte Rosa Therapeutics, Inc. earns an operating margin of -43.8%. Operating margins have expanded from -107.3% to -43.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -16.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 93.2% | 93.2% | 89.3% | — | — | — | — | — |
| Operating Margin | -43.8% | -43.8% | -107.3% | — | — | — | — | — |
| Net Profit Margin | -31.2% | -31.2% | -96.1% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -16.9% | -16.9% | -36.2% | -60.1% | -35.1% | -49.5% | — | — |
| ROA | -8.7% | -8.7% | -19.6% | -41.9% | -30.6% | -35.6% | -118.7% | -72.3% |
| ROIC | -44.2% | -44.2% | -87.8% | -59.6% | -63.6% | — | — | — |
| ROCE | -16.3% | -16.3% | -30.1% | -49.9% | -33.7% | -39.4% | -208.2% | -117.5% |
GLUE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $130M exceeds total debt of $39M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.17 | 0.19 | 0.26 | 0.17 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.39 | -0.81 | -0.46 | -0.03 | -1.00 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | -4.78 | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -29.86 | — | — | -7739.00 |
Net cash position: cash ($130M) exceeds total debt ($39M)
GLUE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Monte Rosa Therapeutics, Inc.'s current ratio of 6.12x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 5.07x to 6.12x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.12 | 6.12 | 2.40 | 5.07 | 10.79 | 20.96 | 1.49 | 2.27 |
| Quick Ratio | 6.12 | 6.12 | 2.40 | 5.07 | 10.79 | 20.96 | 1.49 | 2.27 |
| Cash Ratio | 5.87 | 5.87 | 2.37 | 4.99 | 10.28 | 20.80 | 1.42 | 1.40 |
| Asset Turnover | — | 0.28 | 0.17 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 13.58 | 0.83 | — | — | — | — | — |
GLUE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Monte Rosa Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | 7.4% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $83M | $74M | $51M | $47M | $47M | $44M | $44M |
Peer Comparison
Compare GLUE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 GLUEYou | $1B | -37.2 | — | — | 93.2% | -43.8% | -16.9% | -44.2% | — |
 ARVN | $457M | -5.5 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 KYMR | $7B | -22.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 PRAX | $7B | -18.4 | — | — | — | — | -45.8% | -65.0% | — |
 VRTX | $113B | 29.0 | 22.5 | 35.4 | 85.0% | 39.4% | 22.5% | 23.0% | 0.8 |
 BEAM | $3B | -36.3 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 PTGX | $7B | -53.6 | — | 125.9 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 CRL | $9B | -64.6 | 13.1 | 17.5 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 MEDP | $14B | 31.1 | 23.7 | 19.9 | 30.1% | 21.1% | 70.2% | 154.9% | 0.4 |
 RGEN | $8B | 155.0 | 55.3 | 80.1 | 47.1% | 8.1% | 2.4% | 2.2% | 5.0 |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
What if you invested $1,000 in GLUE 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in GLUE be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs GLUE Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationGLUE vs ARVN — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Arvinas, Inc..
Compare NowGLUE — Frequently Asked Questions
Quick answers to the most common questions about buying GLUE stock.
What is Monte Rosa Therapeutics, Inc.'s P/E ratio?
Monte Rosa Therapeutics, Inc.'s current P/E ratio is -37.2x. This places it at the 50th percentile of its historical range.
What is Monte Rosa Therapeutics, Inc.'s ROE?
Monte Rosa Therapeutics, Inc.'s return on equity (ROE) is -16.9%. The historical average is -39.5%.
Is GLUE stock overvalued?
Based on historical data, Monte Rosa Therapeutics, Inc. is trading at a P/E of -37.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Monte Rosa Therapeutics, Inc.'s profit margins?
Monte Rosa Therapeutics, Inc. has 93.2% gross margin and -43.8% operating margin.